Wilson Therapeutics is a Stockholm, Sweden–based biopharmaceutical company advancing WTX101 (bis-choline tetrathiomolybdate), a novel de-coppering agent. WTX101 is being developed as a new treatment for Wilson's disease, a rare genetic disorder that prevents the body from regulating copper and can lead to serious liver and brain damage. The company is led by CEO Jonas Hansson. Wilson intends to use new funding to advance clinical development of its WTX101 program. Its work is focused on addressing the underlying copper accumulation that causes damage in Wilson's disease. No operating metrics were disclosed in the article.

Total raised

$40M

Funding rounds

1

Latest round

Series B

Latest activity

Apr 2014